18 related articles for article (PubMed ID: 8246352)
1. Cardiac release and kinetics of endothelin after uncomplicated percutaneous transluminal coronary angioplasty.
Krüger D; Giannitsis E; Sheikhzadeh A; Stierle U
Am J Cardiol; 1998 Jun; 81(12):1421-6. PubMed ID: 9645891
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
3. Local changes in the plasma endothelin level in the coronary artery immediately after percutaneous transluminal coronary angioplasty.
Vojácek J; Lisý O; Simek S; Kmonícek P; Rohác J; Jáchymová M; Jindra A
Cardiology; 1997; 88(1):1-5. PubMed ID: 8960617
[TBL] [Abstract][Full Text] [Related]
4. [The diagnosis of myocardial damage during coronary angioplasty by the analysis of the isoforms of the enzyme creatine kinase MB].
Vázquez Rodríguez JM; Hossein-Nia M; Chester M; Leatham E; Holt DW; Kaski JC
Rev Esp Cardiol; 1995 Aug; 48(8):528-36. PubMed ID: 7644806
[TBL] [Abstract][Full Text] [Related]
5. [Quality of life in diabetic patients with coronary artery disease treated with percutaneous coronary angioplasty].
Przewłocki T; Podolec P; Tracz W; Syty M; Piatek J; Ryniewicz W; Pasowicz M; Goncerz G
Przegl Lek; 2000; 57(5):278-82. PubMed ID: 11057117
[TBL] [Abstract][Full Text] [Related]
6. [Percutaneous coronary angioplasty and levels of endothelin-1 in blood].
Chmielk Z; Pszona B; Dabrowski M; Witkowski A; Ruzyłło W
Kardiol Pol; 1993 Oct; 39(10):252-6; discussion 256-7. PubMed ID: 8246352
[TBL] [Abstract][Full Text] [Related]
7. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics. Total Occlusion Study of Canada (TOSCA) Investigators.
Dzavik V; Carere RG; Teo KK; Knudtson ML; Marquis JF; Buller CE
Can J Cardiol; 1998 Jun; 14(6):825-32. PubMed ID: 9676168
[TBL] [Abstract][Full Text] [Related]
8. PET, PTCA, and economic priorities.
Gould KL; Mullani N; Williams B
Clin Cardiol; 1990 Mar; 13(3):153-64. PubMed ID: 2182245
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
